CyFlow™ CD138 PerCP-Cy5.5

CyFlow™ CD138 PerCP-Cy5.5
Alternative Name: B-B4, Syndecan-1
Antigen: CD138
Application: Flow cytometry
Clonality: monoclonal
Clone: B-A38
Emission Maximum: 695 nm
Excitation Maximum: 482 nm
Field of Interest: Immunophenotyping
Format/Fluorochrome: PerCP-Cy5.5
Isotype: IgG1
Laser: Blue , Green
Regulatory Status: RUO
Source Species: Mouse
Target Species: Human
Product number: CU535296

For Research Use Only

$400.34 CAD*

Price excludes any applicable taxes plus shipping costs

Build Your Own Reagent Panel
Quantity 100 tests Volume 0.4 mL Immunogen U266 human peripheral blood myeloma cell... more
CyFlow™ CD138 PerCP-Cy5.5
Quantity100 tests
Volume0.4 mL
ImmunogenU266 human peripheral blood myeloma cell line
Background InformationCD138 (syndecan 1) is a transmembrane proteoglycan that can bind a variety of cytokines and modulate their activity, as well as the activity of extracellular matrix components and influence many developmental processes. CD138 is expressed mainly in differentiating keratinocytes and is transiently upregulated in all layers of the epidermis upon tissue injury. It is also highly expressed on plasma cells and can be detected even on fibroblasts, vascular smooth muscle cells and endothelial cells. Up-regulation and down-regulation of CD138 on the cell surface often correlates with the gain of cancerous characteristics. Serum levels of the shedded soluble sCD138 are used as a prognostic factor of cancerogenesis.
UsageThe reagent is designed for Flow Cytometry analysis of human blood cells. Recommended usage is 4·µl reagent·/ 100·µl of whole blood or 10^6 cells in a suspension. The content of a vial (0.4 ml) is sufficient for 100 tests.
Storage BufferThe reagent is provided in stabilizing phosphate buffered saline (PBS) solution, pH ≈7.4, containing 0.09% (w/v) sodium azide.
StorageAvoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.
StabilityDo not use after expiration date stamped on vial label.
Specific References

| Hayashida K, Johnston DR, Goldberger O, Park PW: Syndecan‑1 expression in epithelial cells is induced by transforming growth factor beta through a PKA‑dependent pathway. J·Biol·Chem. 2006·Aug·25; 281(34):24365‑74. <·PMID:·16807246·> | Manakil JF, Seymour GJ, Bartold PM: Effect of cytokine and antigen stimulation on peripheral blood lymphocyte syndecan‑1 expression. Oral·Microbiol·Immunol. 2007·Aug; 22(4):272‑6. <·PMID:·17600540·> | Muto T, Miyoshi K, Munesue S, Nakada H, Okayama M, Matsuo T, Noma T: Differential expression of syndecan isoforms during mouse incisor amelogenesis. J·Med·Invest. 2007·Aug; 54(3‑4):331‑9. <·PMID:·17878683·> | Choi DS, Kim JH, Ryu HS, Kim HC, Han JH, Lee JS, Min CK: Syndecan‑1, a key regulator of cell viability in endometrial cancer. Int·J·Cancer. 2007·Aug·15; 121(4):741‑50. <·PMID:·17455248·> | Yang Y, MacLeod V, Dai Y, Khotskaya-Sample Y, Shriver Z, Venkataraman G, Sasisekharan R, Naggi A, Torri G, Casu B, Vlodavsky I, Suva LJ, Epstein J, Yaccoby S, Shaughnessy JD Jr, Barlogie B, Sanderson RD: The syndecan‑1 heparan sulfate proteoglycan is a viable target for myeloma therapy. Blood. 2007·Sep·15; 110(6):2041‑8. <·PMID:·17536013·> | Cheriyath V, Glaser KB, Waring JF, Baz R, Hussein MA, Borden EC: G1P3, an IFN‑induced survival factor, antagonizes TRAIL‑induced apoptosis in human myeloma cells. J·Clin·Invest. 2007·Oct; 117(10):3107‑17. <·PMID:·17823654·> | Kuchen S, Robbins R, Sims GP, Sheng C, Phillips TM, Lipsky PE, Ettinger R: Essential role of IL‑21 in B cell activation, expansion, and plasma cell generation during CD4+ T cell‑B cell collaboration. J·Immunol. 2007·Nov·1; 179(9):5886‑96. <·PMID:·17947662·> | Ojeh N, Hiilesvuo K, Wärri A, Salmivirta M, Henttinen T, Määttä A: Ectopic expression of syndecan‑1 in basal epidermis affects keratinocyte proliferation and wound re‑epithelialization. J·Invest·Dermatol. 2008·Jan; 128(1):26‑34. <·PMID:·17625591·> | Jilani I, Wei C, Bekele BN, Zhang ZJ, Keating M, Wierda W, Ferrajoli A, Estrov Z, Kantarjian H, O'Brien SM, Giles FJ, Albitar M: Soluble syndecan‑1 (sCD138 as a prognostic factor independent of mutation status in patients with chronic lymphocytic leukemia. Int·J·Lab·Hematol. 2009·Feb; 31(1):97‑105. <·PMID:·18190591·>

Article successfully added.